{
  "scenario_id": "genomics_gene_therapy_investment_2025",
  "context": "Biopharmaceutical company with $500M annual R&D budget, focusing on rare genetic diseases",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": ["CEO", "Chief Medical Officer", "CFO"],
    "influencers": ["Head of Regulatory Affairs", "VP Clinical Development", "Patient Advocacy Groups"]
  },
  "request": {
    "amount": "$150,000,000",
    "purpose": "Phase 1/2 clinical development of novel gene therapy for rare metabolic disorder",
    "urgency": "high",
    "justification": "Market opportunity in orphan drug space with potential $500M+ annual revenue; addresses unmet medical need with no current treatments"
  },
  "decision_process": [
    {
      "stage": "scientific_review",
      "duration": "4 weeks",
      "activities": ["Preclinical data review", "Target validation assessment", "Competitive landscape analysis"],
      "outcome": "Strong scientific rationale supported by preclinical data"
    },
    {
      "stage": "clinical_development_plan",
      "duration": "6 weeks",
      "activities": ["Trial design development", "Regulatory strategy planning", "Manufacturing feasibility assessment"],
      "outcome": "Comprehensive development plan with clear milestones"
    },
    {
      "stage": "financial_evaluation",
      "duration": "3 weeks",
      "activities": ["NPV analysis", "Risk-adjusted ROI modeling", "Portfolio impact assessment"],
      "outcome": "Positive NPV of $200M with 35% IRR over 10-year horizon"
    },
    {
      "stage": "regulatory_and_ethical_review",
      "duration": "4 weeks",
      "activities": ["FDA consultation", "Ethics committee review", "Patient community engagement"],
      "outcome": "Regulatory pathway clear with strong ethical justification"
    }
  ],
  "business_impact": {
    "expected_revenue": "$750,000,000",
    "projected_market_share": "70% of addressable orphan drug market",
    "risk_factors": ["Clinical trial delays", "Manufacturing scalability challenges", "Regulatory approval uncertainties", "Competitor gene therapy entries"],
    "strategic_alignment": "Advances company's leadership in genetic medicine and expands rare disease portfolio"
  }
}